Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

BrainsWay Ltd. (NASDAQ:BWAY ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Scott Areglado - Senior Vice President and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H.

BrainsWay Ltd. (BWAY) Q4 2022 Earnings Call Transcript

BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2022 financial results and provided an operational update.

BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2022 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 15, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023

Neuronetics Inc

I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, however they are highly unprofitable with volatile sales growth.

Why I Am Passing On BrainsWay And Neuronetics

BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Hadar Levy, the Company's Senior Vice President (SVP) and Chief Operating Officer (COO), and a member of BrainsWay's senior leadership team since 2014, as Chief Executive Officer (CEO). Mr. Levy has been instrumental as a sales, financial and operational leader for the Company throughout his tenure at BrainsWay, previously serving as the Company's Chief Financial Officer and then General Manager North America, before assuming his role as SVP and COO. Mr. Levy succeeds Christopher R. von Jako, Ph.D., who has decided to step down from the Company to pursue other opportunities.

BrainsWay Announces Appointment of Hadar Levy as CEO

David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serve as Board Director David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serve as Board Director

BrainsWay Announces Appointment of Ami Boehm as New Chairman

BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that a major private insurance company in Washington state will extend positive coverage applicable to Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of obsessive-compulsive disorder (OCD) as of February 3, 2023. This policy extension provides coverage of Deep TMS for OCD to approximately 2.2 million members.

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that it has settled litigation filed by Neuronetics, Inc. (“Neuronetics”) in the District of Delaware.

BrainsWay Resolves Neuronetics Litigation

BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported a recent open market purchase of BrainsWay American Depositary Receipts (ADRs) by Yossi Ben Shalom, an independent Director on the Company's Board.

BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom

BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that David Zacut, M.D., BrainsWay's Chairman of the Board of Directors, and Avner Hagai, an independent Director on BrainsWay's Board, separately purchased BrainsWay ordinary shares in recent open market purchases.

BrainsWay Reports Open Market Stock Purchases by Two Board Members

BrainsWay Ltd. (NASDAQ:BWAY ) Q3 2022 Results Earnings Conference Call November 16, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Christopher von Jako - President and Chief Executive Officer Scott Areglado - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Co. Inc. Jeffery Cohen - Ladenburg Thalmann Jayson Bedford - Raymond James & Associates, Inc. Boobalan Pachaiyappan - H.C.

BrainsWay Ltd. (BWAY) Q3 2022 Results - Earnings Call Transcript

Conference call to be held today, November 16, 2022, at 8:30 AM ET Conference call to be held today, November 16, 2022, at 8:30 AM ET

BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights

Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients

BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 16, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Third Quarter Financial Results on November 16, 2022

Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley. The National Alliance on Mental Illness (NAMI) organizes NAMIWalks Your Way events around the country each year to increase mental health awareness, build community, and help raise funds for programs. The Silicon Valley Walk will be Saturday, October 1, 2022. “I am honored to be part of this extremely important event, which aligns with BrainsWay's goal of raising awareness about mental illness and increasing access to mental health resources. I am inspired by the work NAMI does for mental health around the country, and I am looking forward to joining forces at the NAMI Silicon Valley walk,” said Dr. von Jako.

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™

BURLINGTON, Mass. and JERUSALEM, Aug. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced and non-invasive treatment for brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Annual Global Investment Conference being held at the Lotte Palace Hotel in New York City on September 12-14, 2022. Presentation details below:

BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference

Today, there's big news for BrainsWay (NASDAQ: BWAY ) and the company's stakeholders. Reportedly, the U.S. Food and Drug Administration (FDA) granted BrainsWay 510(k) clearance for a unique platform to treat major depressive disorder and depression.

BrainsWay (BWAY) Stock Pops 10% on FDA Clearance News

Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company's 9th FDA Clearance Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company's 9th FDA Clearance

BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression

BrainsWay Ltd. (NASDAQ:BWAY ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Bob Yedid – LifeSci Advisors Christopher von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Steve Lichtman – Oppenheimer Jayson Bedford – Raymond James Jeffery Cohen – Ladenburg Thalmann Raghuram Selvaraju – H.C.

BrainsWay Ltd.'s (BWAY) CEO Christopher von Jako on Q2 2022 Results - Earnings Call Transcript

Revenue Growth of 14% Year-over-Year in Q2 2022

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Second Quarter Financial Results on August 10, 2022

Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Brainsway Ltd. Sponsored ADR (BWAY) Upgraded to Strong Buy: Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 158.6% in Brainsway Ltd. Sponsored ADR (BWAY).

News for Brainsway Stock (BWAY)